336 related articles for article (PubMed ID: 23998966)
1. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD).
Fütterer S; Andrusenko I; Kolb U; Hofmeister W; Langguth P
J Pharm Biomed Anal; 2013 Dec; 86():151-60. PubMed ID: 23998966
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
3. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
5. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations.
Kudasheva DS; Lai J; Ulman A; Cowman MK
J Inorg Biochem; 2004 Nov; 98(11):1757-69. PubMed ID: 15522403
[TBL] [Abstract][Full Text] [Related]
6. Photosynthetic microorganism-mediated synthesis of akaganeite (beta-FeOOH) nanorods.
Brayner R; Yéprémian C; Djediat C; Coradin T; Herbst F; Livage J; Fiévet F; Couté A
Langmuir; 2009 Sep; 25(17):10062-7. PubMed ID: 19572505
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
8. Processing nanoparticles with A4F-SAXS for toxicological studies: Iron oxide in cell-based assays.
Knappe P; Boehmert L; Bienert R; Kamutzki S; Niemann B; Lampen A; Thünemann AF
J Chromatogr A; 2011 Jul; 1218(27):4160-6. PubMed ID: 21129749
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of ultrasmall superparamagnetic iron oxide (USPIO) particles in aqueous suspension by energy dispersive X-ray diffraction (EDXD).
Di Marco M; Port M; Couvreur P; Dubernet C; Ballirano P; Sadun C
J Am Chem Soc; 2006 Aug; 128(31):10054-9. PubMed ID: 16881633
[TBL] [Abstract][Full Text] [Related]
10. [Importance of the different i.v. iron generations for everyday medical practice].
Biggar P; Hahn KM
MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
[TBL] [Abstract][Full Text] [Related]
11. Use of parenteral iron products and serious anaphylactic-type reactions.
Wysowski DK; Swartz L; Borders-Hemphill BV; Goulding MR; Dormitzer C
Am J Hematol; 2010 Sep; 85(9):650-4. PubMed ID: 20661919
[TBL] [Abstract][Full Text] [Related]
12. Evolution of iv iron compounds over the last century.
Macdougall IC
J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
[TBL] [Abstract][Full Text] [Related]
14. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
[TBL] [Abstract][Full Text] [Related]
15. Iron-carbohydrate complexes treating iron anaemia: Understanding the nano-structure and interactions with proteins through orthogonal characterisation.
Krupnik L; Avaro J; Liebi M; Anaraki NI; Kohlbrecher J; Sologubenko A; Handschin S; Rzepiela AJ; Appel C; Totu T; Blanchet CE; Alston AEB; Digigow R; Philipp E; Flühmann B; Silva BFB; Neels A; Wick P
J Control Release; 2024 Apr; 368():566-579. PubMed ID: 38438093
[TBL] [Abstract][Full Text] [Related]
16. Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care.
Bhandari S
NDT Plus; 2011 Jun; 4(Suppl 1):i14-i19. PubMed ID: 27045221
[TBL] [Abstract][Full Text] [Related]
17. Dissolution of iron oxide nanoparticles inside polymer nanocapsules.
Möller J; Cebi M; Schroer MA; Paulus M; Degen P; Sahle CJ; Wieland DC; Leick S; Nyrow A; Rehage H; Tolan M
Phys Chem Chem Phys; 2011 Dec; 13(45):20354-60. PubMed ID: 21993837
[TBL] [Abstract][Full Text] [Related]
18. An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization.
Tabasi O; Razlighi MR; Darbandi MA
Pharm Nanotechnol; 2021; 9(2):157-163. PubMed ID: 33459254
[TBL] [Abstract][Full Text] [Related]
19. How hollow structures form from crystalline iron-iron oxide core-shell nanoparticles in the electron beam.
Herman DA; Cheong S; Banholzer MJ; Tilley RD
Chem Commun (Camb); 2013 Jul; 49(55):6203-5. PubMed ID: 23732792
[TBL] [Abstract][Full Text] [Related]
20. D-mannose-modified iron oxide nanoparticles for stem cell labeling.
Horak D; Babic M; Jendelová P; Herynek V; Trchová M; Pientka Z; Pollert E; Hájek M; Syková E
Bioconjug Chem; 2007; 18(3):635-44. PubMed ID: 17370996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
